These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36412272)

  • 1. A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16-24 months.
    Sharma H; Lalwani S; Parekh S; Pujari P; Shewale S; Palkar S; Hanumante N; Gokhale S; Ks J; Kumar R; Sharma I; Gairola S
    Hum Vaccin Immunother; 2022 Nov; 18(6):2146435. PubMed ID: 36412272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, open label trial to evaluate and compare the immunogenicity and safety of a novel liquid hexavalent DTwP-Hib/Hep B-IPV (EasySix™) to licensed combination vaccines in healthy infants.
    Mohanty L; Sharma S; Behera B; Panwar S; Paliwal C; Gupta A; Chilkoti DC; Singh A
    Vaccine; 2018 Apr; 36(17):2378-2384. PubMed ID: 29580640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
    Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
    Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age.
    Wanlapakorn N; Pruetarat N; Sarawanangkoor N; Phanphanit K; Srimuan D; Thatsanathorn T; Thongmee T; Posuwan N; Poovorawan Y
    Vaccine; 2023 Jun; 41(26):3855-3861. PubMed ID: 37202270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study.
    Romanenko V; Osipova I; Galustyan A; Scherbakov M; Baudson N; Farhi D; Anaya L; Kuriyakose SO; Meyer N; Janssens W
    Hum Vaccin Immunother; 2020 Sep; 16(9):2265-2273. PubMed ID: 32048889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016).
    Guerra A; Costantino C; Martinon-Torres F; Westerholt S; Lambeth C; Chen Z; Lumley J; Marcek T; Johnson D; Wilck M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2310900. PubMed ID: 38327239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immune responses against Haemophilus influenza type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™).
    Wilck MB; Jin Xu Z; Stek JE; Goveia MG; Lee AW
    Vaccine; 2021 Mar; 39(9):1428-1434. PubMed ID: 33541794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Persistence Following Administration of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T and IPV Vaccines and Safety and Immunogenicity of a Booster Dose of DTwP-IPV-HB-PRP~T Administered With an MMR Vaccine in Healthy Infants in India.
    Mangarule S; Siddaiah P; Kawade A; Dhati RM; Padmavathi IV; Palkar S; Tripathi V; Singh R; Palvi K; Mitra M; Shetty R; Leclercq J; Midde VJ; Varghese K; Kandukuri SR; Kukian D; Noriega F
    Pediatr Infect Dis J; 2023 Dec; 42(12):1128-1135. PubMed ID: 37851978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study.
    Susarla SK; Gupta M; Mantan M; Dhongade R; Bhave S; Das RK; Ray RK; Ramesh Babu T; Ravi MD; Krishnamurthy B; James S; Sandhya G; Satish M; Sahoo DP
    Vaccine; 2019 Aug; 37(36):5452-5459. PubMed ID: 31331773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
    Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S
    Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.
    Eregowda A; Lalwani S; Chatterjee S; Vakil H; Ahmed K; Costantini M; Lattanzi M
    Hum Vaccin Immunother; 2013 Sep; 9(9):1903-9. PubMed ID: 23783081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants.
    Wilck MB; Xu ZJ; Stek JE; Lee AW
    Hum Vaccin Immunother; 2021 Jan; 17(1):191-196. PubMed ID: 32750261
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL
    Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Kawade A; Lalwani S; Ravi MD; Kamath V; Mahopatra J; Kulkarni G; Tayade D; Ramanan PV; Uttam KG; Rawal L; Gawande A; Kumar NR; Tiple N; Vagha J; Thakkar P; Khandgave P; Deshmukh BJ; Agarwal A; Dogar V; Gautam M; Jaganathan KS; Kumar R; Sharma I; Gairola S
    NPJ Vaccines; 2024 Feb; 9(1):41. PubMed ID: 38383584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.
    Tapiéro B; Halperin SA; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee AW; Li M; Tomovici A
    Pediatr Infect Dis J; 2013 Jan; 32(1):54-61. PubMed ID: 23241989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
    Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador.
    Suárez E; Asturias EJ; Hilbert AK; Herzog C; Aeberhard U; Spyr C
    Rev Panam Salud Publica; 2010 Feb; 27(2):117-24. PubMed ID: 20339615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.